OncoMatch/Clinical Trials/NCT06888921
A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer
Is NCT06888921 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including COM701 and Normal Saline for ovarian cancer.
Treatment: COM701 · Normal Saline — The goal of this clinical trial is to learn if the experimental antibody COM701 delays the progression of ovarian cancer in participants with Relapsed Platinum Sensitive Ovarian Cancer. It will also learn about the safety of COM701. The main questions the trial aims to answer are: * Does COM701, when used as a maintenance treatment, stop or slow the progression of ovarian cancer? * Does COM701 delay the time to needing a new anti-cancer treatment? * What side effects do participants have when taking COM701? Participants will: * Visit the clinic once every 3 weeks during which the study treatment will be administered intravenously * Undergo various tests and procedures to monitor general health throughout the trial including physical examinations, vital sign measurements (heart rate, blood pressure, breathing, and body temperature), weight measurements, electrocardiography (ECG), blood and urine tests and pregnancy tests if relevant. * Undergo various tests and procedures to assess disease response throughout the trial including tumor imaging by CT scans or MRI to assess the tumor, its location, and size, and the testing of a sample of tumor tissue (from a prior biopsy or a fresh biopsy if feasible, to evaluate tumor response to treatment and to measure levels of tumor markers,
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Prior therapy
Must have received: platinum-based chemotherapy
Has completed at least 2 previous courses (i.e. lines) of platinum-containing therapy
Must have received: platinum-based chemotherapy — last line
For the last chemotherapy course prior to being randomized into the study, must have had a minimum of 4 cycles of a platinum containing regimen and achieved a partial or complete tumor response.
Must have received: bevacizumab (bevacizumab) — maintenance
Has received prior maintenance therapy with bevacizumab or a PARP inhibitor if eligible and is not a candidate for, or has declined in writing, bevacizumab or PARP inhibitor therapy.
Must have received: PARP inhibitor — maintenance
Has received prior maintenance therapy with bevacizumab or a PARP inhibitor if eligible and is not a candidate for, or has declined in writing, bevacizumab or PARP inhibitor therapy.
Cannot have received: cytotoxic chemotherapy
Has had 4 or more lines of cytotoxic chemotherapy in total
Cannot have received: anti-PD-1 therapy
Has had prior treatment with PD-1, PD-L1, anti-PVRIG, TIGIT or any other check point inhibitors
Cannot have received: anti-PD-L1 therapy
Has had prior treatment with PD-1, PD-L1, anti-PVRIG, TIGIT or any other check point inhibitors
Cannot have received: anti-PVRIG therapy
Has had prior treatment with PD-1, PD-L1, anti-PVRIG, TIGIT or any other check point inhibitors
Cannot have received: TIGIT inhibitor
Has had prior treatment with PD-1, PD-L1, anti-PVRIG, TIGIT or any other check point inhibitors
Cannot have received: checkpoint inhibitor
Has had prior treatment with PD-1, PD-L1, anti-PVRIG, TIGIT or any other check point inhibitors
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Georgia Cancer Center at Augusta University · Augusta, Georgia
- The University of Chicago Medical Center · Chicago, Illinois
- Northwestern Memorial Hospital · Warrenville, Illinois
- Massachusetts General Hospital · Boston, Massachusetts
- Corewell Health · Grand Rapids, Michigan
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify